Improved inspiratory function in Duchenne patients on Santhera's Raxone, Phase III data show

13 September 2016

Santhera Pharmaceuticals (SIX: SANN) was trading more than 3% higher on Tuesday afternoon after new Phase III data was published on Raxone (idebenone) on inspiratory function in patients with Duchenne muscular dystrophy (DMD), just days after the granting of orphan drug designation for the same treatment in Australia.

The assessment of dynamic inspiratory function provides valuable information about the degree and progression of pulmonary involvement in patients with DMD.

Data now published in Pediatric Pulmonology from the pivotal DELOS trial showed a statistically-significant improvement in this function among patients using Raxone, as well as other benefits, said Thomas Meier, chief executive of the Swiss drugmaker.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK